ZURICH and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics solutions, announces the launch of Spectronaut® 20 and SpectroMine 5 at the ASMS 2025 Annual Conference, taking place June 1-5 in Baltimore, MD. These major software updates mark significant technological advances in unspecific search performance, immunopeptidomics, and cloud-ready proteomics workflows.
At the core of the new releases is Kuiper, Biognosys' novel search engine, powered by proprietary prediction models specifically optimized for unspecific searches. Kuiper delivers record-breaking peptide identifications, especially for immunopeptidomics applications.
Key Features of Spectronaut® 20:
- Up to 80% more peptide identifications in immunopeptidomics HLA class I workflows
- Accelerated processing with directDIA® runtime improvements
- Enhanced quantitative accuracy for timsTOF data via ion-mobility sensitive algorithms
- Expanded FDR and quality control options
- Improved data visualization, Linux support, and cloud compatibility
- Available on Bruker ProteoScape expanding its capabilities for immunopeptidomics and post-translational modification analysis
Kuiper also powers SpectroMine 5, Biognosys' latest release for DDA-based proteomics, now offering significantly enhanced identification performance. With newly added Linux support, SpectroMine joins Spectronaut in enabling high-throughput proteomics data analysis in cloud and high-performance computing (HPC) environments-enabling scalable, next-generation research workflows.
The applications of Biognosys' next-generation software will be highlighted through multiple scientific posters, two breakfast seminars, and workshop participations. These include two joint presentations with Greywolf Therapeutics on advanced immunopeptidomics workflows, as well as contributions to a workshop on best-practice reporting guidelines for DIA data.
Biognosys will also present its latest technological innovation, the P2 Enrichment System-a robust, nanoparticle-based plasma workflow offering unprecedented depth, reproducibility, and throughput in plasma proteomics. Originally introduced at ASMS 2024, the P2 system will be featured in a new scientific poster and in a presentation by collaborators from Johns Hopkins School of Medicine. Their research demonstrates P2's real-world application in a clinical study on circulating biomarker discovery for advancing early detection of neurodegenerative diseases.
In addition, Biognosys has been invited to deliver an oral presentation on Proteoverse® Digital Proteome, the company's proprietary multi-tissue, multi-species proteome expression atlas. As one of the most comprehensive resources of its kind it provides powerful insights into the proteomic landscape across human and preclinical species, supporting cutting-edge research in drug discovery and translational science.
"Immunopeptidomics is key to understanding how our therapeutics are making a difference for patients. Spectronaut 20 empowers us to leverage complex datasets with greater speed and depth, delivering critical insights into MHC-I antigen modulation and its effects on immune recognition," said Daniel Green, Ph.D., Head of Bioinformatics at Greywolf Therapeutics.
"The P2 Enrichment System from Biognosys was seamlessly transferred to our lab at the Broad Institute. We were impressed by the clarity and robustness of the protocols, as well as the exceptional performance of the technology across our sample sets," said Steven A. Carr, Ph.D., Senior Director of Proteomics and Institute Scientist at the Broad Institute of MIT and Harvard.
For more information on Biognosys' scientific presence at ASMS 2025, please visit: https://biognosys.com/conferences/73rd-asms-conference-2025/
About Spectronaut®
Spectronaut is Biognosys' flagship data analysis software for data-independent acquisition
About Biognosys
Biognosys is a leading contract research organization
Media Contacts
Kristina Beeler, Ph.D.
Chief Product Development and Marketing Officer
kristina.beeler@biognosys.com
